Calla Lily Clinical Care has received a £700,000 Innovate UK grant to adapt its Callavid intravaginal drug-delivery platform for live biotherapeutic products and probiotics intended to support vaginal microbiome health. The award was issued through Innovate UK’s Growth Catalyst Investor Partnerships program, which combines grant funding with matched private investment. It will support a £1 million project co-funded by Innovate UK.
The new initiative, called FLORA, or Focused Lactobacillus Optimised Retention and Adhesion, will examine how Callavid can improve the administration, transfer, retention, and colonization of beneficial Lactobacillus species.
Lactobacillus bacteria play an important role in maintaining a healthy vaginal microbiome. Calla Lily Clinical Care believes its delivery platform could address limitations associated with existing probiotic formats, including leakage, inconsistent dosing, and usability challenges.
Addressing Vaginal Microbiome Imbalances
The FLORA project will focus on vaginal dysbiosis, an imbalance in the vaginal microbiome commonly associated with bacterial vaginosis.
Vaginal dysbiosis has been linked to an increased susceptibility to sexually transmitted infections, including human papillomavirus and HIV. It has also been associated with pelvic inflammatory disease, miscarriage, preterm birth, reduced fertility, and poorer outcomes from in vitro fertilization.
Treatment for common dysbiosis-related conditions remains largely based on antibiotics. However, these conditions can recur after treatment.
The company cited research indicating that bacterial vaginosis returns in approximately 58% of women within 12 months. Repeated antibiotic treatment may also contribute to the broader public health challenge of antimicrobial resistance.
Delivering beneficial Lactobacillus bacteria directly to the relevant location could provide another approach to restoring the vaginal microbiome and potentially reducing the need for repeated courses of antibiotics.
Calla Lily Clinical Care aims to develop Callavid as an over-the-counter product specifically designed to maximize probiotic transfer, retention, and colonization.
The project remains in development, and the platform’s effectiveness for this indication will need to be established through laboratory work and any required clinical and regulatory processes.
Developing A Model To Measure Colonization
Alongside the device adaptation, Calla Lily Clinical Care plans to develop a proprietary laboratory model for evaluating bacterial colonization.
The model is expected to help the company assess how effectively different bacteria are transferred and retained. Data generated through the system could also inform the development of future vaginal microbiome products.
FLORA expands Callavid beyond its initial applications involving progesterone and antibiotics. The platform is designed to optimize the delivery of therapies administered intravaginally.
This is the third distinct application of Callavid to receive competitive external funding.
The National Institute for Health and Care Research has funded development involving progesterone for threatened miscarriage. Wellcome Leap is supporting work on targeted antibiotic delivery intended to spare the gut microbiome. The Innovate UK award now adds live biotherapeutic products and probiotics for vaginal microbiome health.
Third Innovate UK Award For Calla Lily
The FLORA grant is the third Innovate UK award secured by Calla Lily Clinical Care.
The company is also conducting the FREEDOM trial, which is funded by the National Institute for Health and Care Research. The study is evaluating a 400-milligram progesterone formulation delivered through Callavid in patients diagnosed with luteal phase insufficiency.
Luteal phase insufficiency is associated with an increased risk of infertility and miscarriage. The FREEDOM trial is fully enrolled and approaching completion.
Calla Lily Clinical Care also joined Wellcome Leap’s $50 million Focused Antibiotics program in 2026. That initiative is working to change how antibiotics are delivered while addressing antimicrobial resistance objectives.
The three funded applications demonstrate the company’s attempt to establish Callavid as a platform rather than a delivery system intended for only one therapeutic product.
Calla Lily Clinical Care is a clinical-stage women’s health company. Its work focuses on improving the delivery of therapies for reproductive and vaginal health conditions.
KEY QUOTES:
“Innovate UK has backed us from our earliest days and helped us build Callavid capital-efficiently. This third award takes us into an entirely new area. In under two years, the Callavid platform has won competitive funding for three different therapies: progesterone, antibiotics, and now live biotherapeutics and probiotics. The vaginal microbiome is one of the most exciting frontiers in women’s health, but even the best bacteria will only help if they reach the right place and stay there. This is where Callavid can make a real difference for women.”
Thang Vo-Ta, Co-Founder and Chief Executive Officer of Calla Lily Clinical Care
“Over my career I have seen promising medicines fall short not because the science was wrong, but because getting them to the right place in the body proved harder than anyone expected. The vaginal microbiome is a clear example. The science behind live biotherapeutics is moving quickly, yet how they are delivered has had far less attention. If we can help women restore and maintain a healthy microbiome, we may improve her quality of life and reduce how often she will need repeated courses of antibiotics, lowering the potential for resistance that affects us all. Calla Lily has already taken Callavid from concept into the clinic, and this award gives the team the chance to tackle that delivery problem head on.”
Dr. Annalisa Jenkins, Advisor to Calla Lily Clinical Care, Former Chief Executive Officer of Dimension Therapeutics, and Chair of Ori Biotech

